Ignyta Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ignyta Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8244
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ignyta Inc (Ignyta), formerly NexDx Inc, a subsidiary of F. Hoffmann-La Roche Ltd, is a cancer care service provider. The company discovers, develops and commercializes new drugs targeting activated genes in cancer cells. It develops products using integrated therapeutic technology (Rx/Dx). Ignyta’s pipeline products include entrectinib, RXDX-105, taladegib and RXDX-106. The company’s entrectinib product is designed to target cancers harboring activating molecular alterations. Its RXDX-106 is a novel small molecule immunomodulatory agent with potent anti-tumor activity. Ignyta offers clinical trials and research and development services. The company serves cancer patients and pharmaceuticals industries. Ignytais headquartered in San Diego, California, the US.

Ignyta Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ignyta Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ignyta Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ignyta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ignyta Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Ignyta Acquires Four Oncology R&D Assets from Cephalon 11
Venture Financing 13
NexDx Raises US$5.5 Million In Series B Financing 13
Partnerships 14
Ignyta and Institut Curie Enter into Partnership 14
Ignyta Enters into Research Agreement with Moffitt Cancer Center 15
Merger 16
Ignyta And Infinity Oil & Gas Merge In Reverse Merger Transaction 16
Licensing Agreements 17
Ignyta Amends Licensing Agreement with Eli Lilly 17
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors 19
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences 21
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for Tyrosine Kinase Inhibitors 22
Equity Offering 24
Ignyta Prices Public Offering of Shares for USD160 Million 24
Ignyta Raises USD88.4 Million in Public Offering of Shares 26
Ignyta Raises USD57.5 Million in Public Offering of Shares 28
Ignyta Raises USD30 Million in Private Placement of Shares 30
Ignyta Raises USD75 Million in Public Offering of Shares 31
Ignyta Raises USD42 Million in Private Placement of Shares 33
Ignyta Completes Public Offering Of Shares For US$55.2 Million 34
Ignyta Completes Private Placement Of Shares For US$7.8 Million 36
Ignyta Completes Private Placement Of Shares For US$46.2 Million 37
Acquisition 38
Roche Acquires Ignyta for USD1.7 Billion 38
Ignyta Acquires Actagene Oncology 40
Ignyta Inc – Key Competitors 41
Ignyta Inc – Locations And Subsidiaries 42
Head Office 42
Recent Developments 43
Financial Announcements 43
Nov 07, 2017: Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results 43
Aug 08, 2017: Ignyta Announces Second Quarter 2017 Company Highlights and Financial Results 45
May 01, 2017: Ignyta Announces First Quarter 2017 Company Highlights and Financial Results 47
Mar 14, 2017: Ignyta Announces Full Year 2016 Company Highlights and Financial Results 49
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Ignyta Inc, Pharmaceuticals & Healthcare, Key Facts 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ignyta Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ignyta Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ignyta Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ignyta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ignyta Acquires Four Oncology R&D Assets from Cephalon 11
NexDx Raises US$5.5 Million In Series B Financing 13
Ignyta and Institut Curie Enter into Partnership 14
Ignyta Enters into Research Agreement with Moffitt Cancer Center 15
Ignyta And Infinity Oil & Gas Merge In Reverse Merger Transaction 16
Ignyta Amends Licensing Agreement with Eli Lilly 17
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors 19
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences 21
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for Tyrosine Kinase Inhibitors 22
Ignyta Prices Public Offering of Shares for USD160 Million 24
Ignyta Raises USD88.4 Million in Public Offering of Shares 26
Ignyta Raises USD57.5 Million in Public Offering of Shares 28
Ignyta Raises USD30 Million in Private Placement of Shares 30
Ignyta Raises USD75 Million in Public Offering of Shares 31
Ignyta Raises USD42 Million in Private Placement of Shares 33
Ignyta Completes Public Offering Of Shares For US$55.2 Million 34
Ignyta Completes Private Placement Of Shares For US$7.8 Million 36
Ignyta Completes Private Placement Of Shares For US$46.2 Million 37
Roche Acquires Ignyta for USD1.7 Billion 38
Ignyta Acquires Actagene Oncology 40
Ignyta Inc, Key Competitors 41

List of Figures
Ignyta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ignyta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ignyta Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Ignyta Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gevo, Inc.:企業のM&A・事業提携・投資動向
    Gevo, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gevo, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • BASF India Ltd (BASF):企業の財務・戦略的SWOT分析
    Summary BASF India Ltd (BASF) a subsidiary of BASF SE is a chemical company that manufactures and distributes specialty chemicals, performance products, plastics and crop protection products. The company’s chemical products include intermediates, monomers and petrochemicals. Its performance products …
  • Assystem SA (ASY):企業の財務・戦略的SWOT分析
    Assystem SA (ASY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Align Technology Inc (ALGN):企業の財務・戦略的SWOT分析
    Align Technology Inc (ALGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Castle View International Holdings Limited:企業の戦略・SWOT・財務情報
    Castle View International Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Castle View International Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Quark Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Quark Pharmaceuticals Inc (Quark), a subsidiary of SBI Biotech Co Ltd, is a clinical-stage pharmaceutical company in the development of novel RNAi-based therapeutics. It offers under development products which include PF-655, a synthetic siRNA which is used for the treatment of diabetic macu …
  • True Value Company:企業の戦略・SWOT・財務情報
    True Value Company - Strategy, SWOT and Corporate Finance Report Summary True Value Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Peptilogics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Peptilogics Inc (Peptilogics) is an early-stage biotechnology company that develops novel peptide therapeutics. The company’s antibiotics address the epidemic of multidrug-resistant bacterial infections. Its products portfolio includes engineered Cationic Antibiotic Peptides (eCAP) technolog …
  • Stemgent Inc-製薬・医療分野:企業M&A・提携分析
    Summary Stemgent Inc (Stemgent), a part of the ReproCELL Group is a biotechnology company that focuses on the development of innovative technology and application solutions for the advancement of stem cell research. The company’s product portfolio comprises antibodies, cell lines, cytokines / protei …
  • Matra Petroleum Plc:石油・ガス:M&Aディール及び事業提携情報
    Summary Matra Petroleum Plc (Matra Petroleum), formerly Ming Resources, is an independent oil and gas exploration and production company that acquires, explores, develops, and produces oil and gas properties in the US. The company owns 27 leases located in the Texas Panhandle region covering an area …
  • Liechtensteinische Landesbank Ag:企業の戦略・SWOT・財務分析
    Liechtensteinische Landesbank Ag - Strategy, SWOT and Corporate Finance Report Summary Liechtensteinische Landesbank Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Taurus International MFG, Inc.:企業の戦略・SWOT・財務情報
    Taurus International MFG, Inc. - Strategy, SWOT and Corporate Finance Report Summary Taurus International MFG, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • MLM Biologics Inc:製品パイプライン分析
    Summary MLM Biologics Inc (MLM Biologics) is a medical device company that provides optimum wound care management for patients and doctors. The company’s product includes bio-ConneKt Wound Matrix, a collagen-based wound dressing for wounds such as chronic vascular ulcers, draining wounds, partial an …
  • NovioSense BV:医療機器:M&Aディール及び事業提携情報
    Summary NovioSense BV (NovioSense) is a medical device company that develops a wireless technology platform for non-invasive monitoring of disease biomarkers. The company offers NovioSense, a glucose sensor to monitor glucose levels in the tear fluid and sends a wireless signal to a handheld unit or …
  • Metinvest BV:企業の戦略・SWOT・財務分析
    Metinvest BV - Strategy, SWOT and Corporate Finance Report Summary Metinvest BV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Invenra Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Invenra Inc (Invenra) is a biotechnology company that discovers and develops multispecific antibodies for immuno-oncology. The company’s pipeline products include t-cell redirecting b-bodies, OX40 agonist, treg depleter SNIPER and exelixis B-Body. Its B-Body and SNIPER technologies are used …
  • GGP Inc:戦略・SWOT・企業財務分析
    GGP Inc - Strategy, SWOT and Corporate Finance Report Summary GGP Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • United BioPharma Inc (6471):製薬・医療:M&Aディール及び事業提携情報
    Summary United BioPharma Inc (United BioPharma) is a pharmaceutical company. The company develops, manufactures, and markets monoclonal antibody (mAb) products and biosimilar antibodies. Its molecules product pipeline includes UB-421, a monoclonal antibody for AIDS treatment; and UB-621, an anti-her …
  • LifeArc:企業のM&A・事業提携・投資動向
    LifeArc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's LifeArc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Terna SpA (TRN)-エネルギー分野:企業M&A・提携分析
    Summary Terna S.p.A. (Terna) is an electricity transmission system operator (TSO). It operates high-voltage grid and carries out transmission and dispatching of electricity, maintains transmission infrastructure, plans and constructs the grid, and undertakes grid development projects. It offers spec …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆